Vioxx (rofecoxib) for osteoarthritis, acute pain, and primary dysmenorrhea

December 1999

Merck Frosst is now introducing Vioxx (rofecoxib) for osteoarthritis, acute pain, and primary dysmenorrhea.

It's a new COX-2 inhibitor...similar to Celebrex (celecoxib).

Vioxx and Celebrex are comparable to NSAIDs for reducing pain and inflammation...but the new drugs MIGHT cause fewer ulcers.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

highlighting the value of pharmacists' interventions
Neurology & Pain Zanaflex (tizanidine), a new drug for muscle spasticity
Neurology & Pain a new drug for advanced Parkinson's disease called Comtan (entacapone, Novartis)
Diabetes many patients with type 1 diabetes don't realize when their blood sugar is too low to drive safely
Vioxx (rofecoxib) for osteoarthritis, acute pain, and primary dysmenorrhea
Migraine whether patients on SSRIs can use one of the "triptans" for migraines
Infectious Diseases new flu drug, Relenza (zanamivir)
Infectious Diseases Do all the new antibacterial soaps, lotions, and gels really help prevent colds and flu
Ophthalmology more people taking lutein for cataracts and macular degeneration
Women's Health estrogen replacement therapy reduces the risk of colorectal cancer
natural products for the cold and flu season
Cardiology low-molecular-weight heparin for unstable angina and non-Q-wave heart attacks
Cardiology amiodarone (Cordarone IV) to help resuscitate cardiac arrest victims
Lots of people are using magnets